deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT03012061

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

A Phase IIb, 24 Week, Randomized, Double-blind, 3 Arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of Two Doses of Umeclidinium Bromide Administered Once-daily Via a Dry Powder Inhaler, Versus Placebo, in Participants With Asthma

Sponsor: GlaxoSmithKline

Conditions Asthma
Interventions Albuterol/salbutamol Fluticasone Furoate Placebo UMEC
Updated 18 times since 2017 Last updated: Oct 6, 2020 Started: Jan 25, 2017 Primary completion: May 30, 2018 Completion: May 30, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Asthma, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 18 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Apr 2018 · 3 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Jul 2019 · 12 months · monthly snapshot~Jul 2019 – ~Nov 2020 · 16 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 13 earlier versions

  1. Jul 2019 — Nov 2020 [monthly]

    Completed PHASE2

  2. Jul 2018 — Jul 2019 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE2

  4. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2018 — Apr 2018 [monthly]

    Active Not Recruiting PHASE2

  6. Dec 2017 — Jan 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  8. Aug 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  9. Jun 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

  10. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

  11. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE2

  12. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE2

  13. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jan 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arkhangelsk, Russia , Barnaul, Russia , Bialystok, Poland , Brampton, Canada , Brasov, Romania , Bucharest, Romania , Burlington, Canada , Calgary, Canada , Cincinnati, United States , Cluj-Napoca, Romania and 55 more locations